tiprankstipranks
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Germany Market
38I
Intellia Therapeutics
RESEARCH TOOLSreports

Intellia Therapeutics (38I) Stock Forecast & Price Target

13 Followers
See the Price Targets and Ratings of:

38I Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
8 Buy
8 Hold
1 Sell
Based on 17 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

38I Stock 12 Month Forecast

Average Price Target

€17.84
▲(49.71% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is €17.84 with a high forecast of €41.54 and a low forecast of €6.06. The average price target represents a 49.71% change from the last price of €11.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","42":"€42","14.25":"€14.25","23.5":"€23.5","32.75":"€32.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41.54017104,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€41.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.8449651426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€17.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.05794161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14.25,23.5,32.75,42],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,13.118474695384615,15.48694939076923,17.855424086153846,20.22389878153846,22.592373476923076,24.960848172307692,27.329322867692305,29.69779756307692,32.06627225846154,34.43474695384615,36.803221649230764,39.171696344615384,{"y":41.54017104,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,11.29576654943077,11.841533098861538,12.387299648292307,12.933066197723077,13.478832747153845,14.024599296584615,14.570365846015385,15.116132395446154,15.661898944876922,16.20766549430769,16.75343204373846,17.29919859316923,{"y":17.8449651426,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.75,10.389072431538462,10.028144863076923,9.667217294615385,9.306289726153846,8.945362157692308,8.584434589230769,8.223507020769231,7.862579452307692,7.501651883846154,7.140724315384615,6.779796746923077,6.418869178461539,{"y":6.05794161,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€41.54Average Price Target€17.84Lowest Price Target€6.06
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
€16.26
Hold
36.43%
Upside
Reiterated
03/24/26
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
JonesTrading Analyst forecast on DE:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
€24.82
Buy
108.23%
Upside
Upgraded
03/04/26
Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)
Wedbush Analyst forecast on DE:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
€10.27
Hold
-13.84%
Downside
Reiterated
03/03/26
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
Canaccord Genuity Analyst forecast on DE:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€46.22→€41.08
Buy
244.66%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target lowered to $48 from $54 at CanaccordIntellia Therapeutics price target lowered to $48 from $54 at Canaccord
Citizens JMP Analyst forecast on DE:38I
Silvan Tuerkcan
Citizens JMP
Citizens JMP
€17.97→€23.97
Buy
101.05%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target raised to $28 from $21 at CitizensIntellia Therapeutics price target raised to $28 from $21 at Citizens
Wells Fargo Analyst forecast on DE:38I
Yanan Zhu
Wells Fargo
Wells Fargo
€10.27→€12.84
Hold
7.71%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target raised to $15 from $12 at Wells FargoIntellia Therapeutics price target raised to $15 from $12 at Wells Fargo
H.C. Wainwright Analyst forecast on DE:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€21.4→€25.68
Buy
115.41%
Upside
Reiterated
03/03/26
H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)
Truist Financial Analyst forecast on DE:38I
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)
William Blair Analyst forecast on DE:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Upgraded
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Chardan Capital Analyst forecast on DE:38I
Geulah Livshits
Chardan Capital
Chardan Capital
€23.11
Buy
93.87%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Morgan Stanley Analyst forecast on DE:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
€9.41
Hold
-21.02%
Downside
Reiterated
03/02/26
Balancing Reduced Regulatory Risk and Ongoing Development Uncertainty: Rationale for Maintaining a Hold Rating
J.P. Morgan Analyst forecast on DE:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on DE:38I
Luca Issi
RBC Capital
RBC Capital
€7.7→€12.84
Hold
7.71%
Upside
Reiterated
03/02/26
RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
TD Cowen Analyst forecast on DE:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)
Evercore ISI Analyst forecast on DE:38I
Jonathan Miller
Evercore ISI
Evercore ISI
€6.85→€11.98
Hold
0.52%
Upside
Reiterated
01/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Viridian Therapeutics (NASDAQ: VRDN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on DE:38I
Alec Stranahan
Bank of America Securities
Bank of America Securities
€16.26
Hold
36.43%
Upside
Reiterated
03/24/26
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)
JonesTrading Analyst forecast on DE:38I
Debanjana Chatterjee
JonesTrading
JonesTrading
€24.82
Buy
108.23%
Upside
Upgraded
03/04/26
Analysts Offer Insights on Healthcare Companies: Rigel (NASDAQ: RIGL), Arcturus Therapeutics (NASDAQ: ARCT) and Intellia Therapeutics (NASDAQ: NTLA)
Wedbush Analyst forecast on DE:38I
Unknown Analyst
Wedbush
Not Ranked
Wedbush
€10.27
Hold
-13.84%
Downside
Reiterated
03/03/26
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
Canaccord Genuity Analyst forecast on DE:38I
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€46.22→€41.08
Buy
244.66%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target lowered to $48 from $54 at CanaccordIntellia Therapeutics price target lowered to $48 from $54 at Canaccord
Citizens JMP Analyst forecast on DE:38I
Silvan Tuerkcan
Citizens JMP
Citizens JMP
€17.97→€23.97
Buy
101.05%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target raised to $28 from $21 at CitizensIntellia Therapeutics price target raised to $28 from $21 at Citizens
Wells Fargo Analyst forecast on DE:38I
Yanan Zhu
Wells Fargo
Wells Fargo
€10.27→€12.84
Hold
7.71%
Upside
Reiterated
03/03/26
Intellia Therapeutics price target raised to $15 from $12 at Wells FargoIntellia Therapeutics price target raised to $15 from $12 at Wells Fargo
H.C. Wainwright Analyst forecast on DE:38I
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
€21.4→€25.68
Buy
115.41%
Upside
Reiterated
03/03/26
H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)
Truist Financial Analyst forecast on DE:38I
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Intellia Therapeutics (NASDAQ: NTLA) and Immunic (NASDAQ: IMUX)
William Blair Analyst forecast on DE:38I
Myles Minter
William Blair
William Blair
―
Buy
―
Upgraded
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Chardan Capital Analyst forecast on DE:38I
Geulah Livshits
Chardan Capital
Chardan Capital
€23.11
Buy
93.87%
Upside
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Intellia Therapeutics (NASDAQ: NTLA) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Morgan Stanley Analyst forecast on DE:38I
Terence Flynn
Morgan Stanley
Morgan Stanley
€9.41
Hold
-21.02%
Downside
Reiterated
03/02/26
Balancing Reduced Regulatory Risk and Ongoing Development Uncertainty: Rationale for Maintaining a Hold Rating
J.P. Morgan Analyst forecast on DE:38I
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Intellia Therapeutics (NASDAQ: NTLA) and Sarepta Therapeutics (NASDAQ: SRPT)
RBC Capital Analyst forecast on DE:38I
Luca Issi
RBC Capital
RBC Capital
€7.7→€12.84
Hold
7.71%
Upside
Reiterated
03/02/26
RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
TD Cowen Analyst forecast on DE:38I
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
02/26/26
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)
Evercore ISI Analyst forecast on DE:38I
Jonathan Miller
Evercore ISI
Evercore ISI
€6.85→€11.98
Hold
0.52%
Upside
Reiterated
01/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA) and Viridian Therapeutics (NASDAQ: VRDN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months
xxx
Success Rate
14/35 ratings generated profit
40%
Average Return
+13.86%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +13.86% per trade.
1 Year
Gena WangBarclays
Success Rate
10/26 ratings generated profit
38%
Average Return
-12.89%
Copying Gena Wang's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of -12.89% per trade.
2 Years
xxx
Success Rate
5/16 ratings generated profit
31%
Average Return
-24.42%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 31.25% of your transactions generating a profit, with an average return of -24.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

38I Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
15
7
2
6
5
Buy
7
5
3
5
3
Hold
20
22
13
22
11
Sell
1
1
0
1
1
Strong Sell
0
0
0
0
0
total
43
35
18
34
20
In the current month, 38I has received 8 Buy Ratings, 11 Hold Ratings, and 1 Sell Ratings. 38I average Analyst price target in the past 3 months is 17.84.
Each month's total comprises the sum of three months' worth of ratings.

38I Financial Forecast

38I Earnings Forecast

Next quarter’s earnings estimate for 38I is -€0.78 with a range of -€0.94 to -€0.62. The previous quarter’s EPS was -€0.71. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s earnings estimate for 38I is -€0.78 with a range of -€0.94 to -€0.62. The previous quarter’s EPS was -€0.71. 38I beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Sales Forecast

Next quarter’s sales forecast for 38I is €11.63M with a range of €0.00 to €19.79M. The previous quarter’s sales results were €19.73M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.
Next quarter’s sales forecast for 38I is €11.63M with a range of €0.00 to €19.79M. The previous quarter’s sales results were €19.73M. 38I beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 38I has Performed in-line its overall industry.

38I Stock Forecast FAQ

What is DE:38I’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 17.84.
    What is DE:38I’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 49.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Intellia Therapeutics a Buy, Sell or Hold?
          Intellia Therapeutics has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 8 hold ratings and 1 sell ratings.
            What is Intellia Therapeutics’s share price target?
            The average share price target for Intellia Therapeutics is 17.84. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €41.54 ,and the lowest forecast is €6.06. The average share price target represents 49.71% Increase from the current price of €11.92.
              What do analysts say about Intellia Therapeutics?
              Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Intellia Therapeutics?
                To buy shares of DE:38I, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.